glp 1 for depression GLP-1 Drug Improved Motivation in Major Depressive Disorder Study reveals GLP-1 medications may

High purity lyophilized powder for mitochondrial and metabolic research New ADVBioLabs Melanotan I 10mg Research Peptide COA Verified High Purity mt-1 Research Use Only Peptide Compounds Peptide Compounds Melanotan I 10mg Research Peptide COA Verified High Purity $60.00 Melanotan I 10mg Research Peptide | MC1R Agonist | COA Verified Melanotan I 10mg New ADVBioLabs Epitalon 50mg Research Peptide COA Verified High Purity epi50 Research Use Only Cellular Research Cellular Research Epitalon 50mg Research Peptide COA Verified High Purity $150.00 Epitalon 50mg Research Peptide | Telomere & Cellular Ageing Research | COA Verified Epitalon All products are for research and laboratory use only

Wearable devices beyond activity trackers in youth with obesity: Summary of options

Obstructive Sleep Apnea SURMOUNT-OSA trials investigated GLP2 in adults with moderate-to-severe obstructive sleep apnea and obesity: Significant improvements in apnea-hypopnea index (AHI) from baseline Benefits observed in participants both using and not using positive airway pressure therapy Improvements correlated with weight reduction FDA approval granted in December 2024 for moderate-to-severe OSA treatment Diabetes Prevention Extended follow-up from SURMOUNT-1 assessed diabetes prevention in participants with prediabetes: 94% reduction in progression to type 2 diabetes compared to placebo over 3 years Nearly all participants with prediabetes at baseline converted to normoglycemia Effects diminished during off-treatment follow-up period, indicating ongoing treatment benefit [CALLOUT BOX Highlighted] Important Context: While GLP2 has demonstrated substantial efficacy in multiple large-scale clinical trials, the majority of data comes from industry-sponsored studies with relatively short follow-up periods (40-72 weeks for most trials)

GLP-1 Market: Novo vs Eli Lilly in $58B Showdown $58B GLP-1 Weight Loss Showdown The GLP-1 market is turning into a high-stakes battle between two pharmaceutical giants: Novo Nordisk Wegovy & Ozempic Eli Lilly Zepbound & Mounjaro Key points: Explosive growth: Already exceeding $58 billion in market size and accelerating rapidly